Clinic
Healthy Urgent Care, PLLC
Healthy Urgent Care, PLLC was paid $3.21M by Medicaid between Jan 2018 and Dec 2024, across 48 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoHEALTHY URGENT CARE, PLLC
NEW HUDSON, MI 48165
NEW HUDSON, MI 48165
33aNPI1124266754assigned 02/04/2009
33bProvider typeUrgent Care Clinic/Center
28Total paid$3.21M
24GClaims80,005
24DCodes billed48
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Michigan
Rank by total paid#25 of 239
Median peer was paid$346K
This provider vs. median9.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,073 | $694K | |
| 2019 | 13,306 | $563K | |
| 2020 | 9,511 | $372K | |
| 2021 | 19,718 | $769K | |
| 2022 | 14,259 | $485K | |
| 2023 | 4,896 | $200K | |
| 2024incomplete | 2,242 | $130K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 18,898 | 17,264 | $1.19M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 18% | 6,909 | 6,682 | $582K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 10,905 | 10,154 | $544K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 10% | 5,225 | 5,163 | $325K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.4% | 6,585 | 6,102 | $204K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 1,928 | 1,802 | $78K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.8% | 568 | 542 | $58K |
| 99058 | 1.5% | 929 | 827 | $50K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.4% | 4,135 | 4,034 | $44K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 3,152 | 1,580 | $38K |
| 99000 | <1% | 7,444 | 6,953 | $23K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,719 | 1,567 | $22K |
36 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,756 | $13K |
| 86328 | <1% | 167 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 32 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 521 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 109 | $3K |
| 81002 | <1% | 1,814 | $3K | |
| 73630 | <1% | 208 | $3K | |
| 81003 | <1% | 1,644 | $2K | |
| 81025 | <1% | 537 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 52 | $2K |
| 73130 | <1% | 140 | $2K | |
| 93000 | <1% | 248 | $2K | |
| S9083 | Global fee urgent care centers | <1% | 2,338 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 756 | $1K |
| 74022 | <1% | 41 | $791.77 | |
| 73610 | <1% | 57 | $782.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 451 | $639.72 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 40 | $485.50 |
| 73564 | <1% | 24 | $399.42 | |
| 73110 | <1% | 15 | $263.45 | |
| 74019 | <1% | 19 | $252.33 | |
| 86308 | <1% | 59 | $202.19 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 45 | $199.87 |
| 87807 | <1% | 25 | $193.30 | |
| 69210 | <1% | 14 | $177.71 | |
| 87430 | <1% | 35 | $152.38 | |
| 73562 | <1% | 16 | $143.80 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $70.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 73 | $52.13 |
| 82962 | <1% | 25 | $48.78 | |
| 99072 | <1% | 210 | $25.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 66 | $0.06 |
| 99173 | 0% | 14 | $0.00 | |
| J7610 | Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg | 0% | 15 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 14 | $0.00 |
| 94760 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSINAWI, SARMED (CEO)